arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BIOLARGO, INC.

BLGO
Price unavailable
Materials ·Chemicals & Allied Products ·USChemicals & Allied Products
17 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

BIOLARGO, INC. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth -56.3%
Op. Margin -191.3%
ROIC -191.7%
FCF / Share $-0.03
Trailing P/E
Price / Book
FCF Yield
Debt / Equity 0.51
info Valuation on last close.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.76M
↓ -56.3%
Net Income Profit after all expenses
$-15.19M
↓ -249.4%
Operating Margin Operating profit as % of sales
-191.3%
↓ -685.3% 0th
FCF / Share Free cash flow per share
$-0.03
↓ -151.3%
Long-Term Debt Long-term obligations
$2.08M
↑ +92.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Financial Health
36
Cash Quality
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters